RxDoctor Payments Data

Jonathan Alvior, MD

Internal Medicine · Tampa, FLNPI 1154513067

Payments from drug & device makers

$10,687in general payments, 2019–2025

Across 420 payments — averaging $25.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Novo Nordisk$990
  • Bayer$731
  • Lilly USA, LLC$596
  • Novartis$563
  • Boehringer Ingelheim$546
  • plus $5K from 33 others

What the payments were for

  • Food & beverage$10,672100%
  • Education$150%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,687 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$441,610
Medicare patients
286
Services billed
3,516

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban168$77,349
FarxigaDapagliflozin Propanediol42$54,020
OzempicSemaglutide44$51,217
TrulicityDulaglutide33$45,954
JardianceEmpagliflozin66$37,544
JanuviaSitagliptin Phosphate44$31,492
XareltoRivaroxaban35$27,417
TradjentaLinagliptin26$19,211
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$18,482
NuedextaDextromethorphan Hbr/Quinidine26$17,893
EntrestoSacubitril/Valsartan18$15,346
KerendiaFinerenone19$13,467
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog13$10,457
MyrbetriqMirabegron32$10,357
Combivent RespimatIpratropium/Albuterol Sulfate16$8,310

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$508$77,349168 claims
Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat$546$65,064108 claims
AstraZenecaFarxiga$1,897$54,02042 claims
Novo NordiskOzempic$990$51,21744 claims
Lilly USA, LLCTrulicity, Humulin 70-30$596$48,16556 claims
MerckJanuvia$26$31,49244 claims
Johnson & JohnsonXarelto$235$27,41735 claims
GSKTrelegy Ellipta$466$18,48224 claims
NovartisEntresto$563$15,34618 claims
BayerKerendia$731$13,46719 claims
Astellas Pharma US IncMyrbetriq$90$10,35732 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →